Breast Cancer: Updated and Deep Insights
Published: 2023-05-26
Page: 104-118
Issue: 2023 - Volume 6 [Issue 1]
Kimberly Morton Cuthrell *
Saint James School of Medicine, United States.
Nikolaos Tzenios
Public Health and Medical Research, Charisma University, Grace Bay, Turks and Caicos Islands.
*Author to whom correspondence should be addressed.
Abstract
Breast cancer is the most common cancer diagnosed in females throughout the entire world, and it is also the primary reason why people lose their lives due to malignant tumors. The risk of developing breast cancer is increasing at an alarming rate over the whole planet. In light of this, it is essential to search for innovative therapeutic techniques in addition to predictive and prognostic indicators, notwithstanding the progress that has been made in identifying and treating the disease, which has resulted in a reduction in the overall mortality rate. Several distinct therapy modalitieutilized, each of which is determined by the molecular subtype. Systemic therapy and locoregional therapy, which include surgery and radiation therapy, are both components of the multidisciplinary strategy that is taken to treat breast cancer. Chemotherapy, anti-HER2 therapy for diseases that are positive for HER2, hormone therapy for diseases that are positive for hormones, and immunotherapy, which was developed more recently, are all examples of systemic therapies. Triple negative breast cancer accounts for between 15% and 20% of all breast cancers. This subtype of breast cancer affects more than 15% of patients. As a result of its poor response to treatment and the exceedingly invasive nature of the condition, it presents a therapeutic challenge and, as a result, generates a significant amount of research interest. The treatment of breast cancer in the future will hopefully be more individualized, with the ability to de-escalate when necessary and escalate when necessary based on the biology of the tumor as well as an early therapeutic response. This article provides an overview of the research that has been done on breast carcinoma, which is a disorder that affects women all around the world.
Keywords: Breast cancer, therapy, etiology, breast cancer stages, cancer history
How to Cite
Downloads
References
Global regional and national age-sex-specific mortality for 282 causes of death in 195 countries and territories 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392.
Rozenblatt-Rosen O, et al. The human tumor atlas network: Charting tumor transitions across space and time at single-cell resolution. Cell. 2020;181.
Siegel RL, Miller KD, Jemal A. Cancer statistics 2020. CA: A Cancer Journal for Clinicians. 2020;70.
Thomas F, et al. Evolutionary ecology of organs: A missing link in cancer development? Trends Cancer. 2016;2.
Tomasetti C, Li L, Vogelstein B. Stem cell divisions somatic mutations cancer etiology and cancer prevention. Science. 2017;355.
Zahir N, et al. Characterizing the ecological and evolutionary dynamics of cancer. Nature Genetics. 2020;52.
Arbyn M, et al. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health. 2020;8.
Armitage EG, Ciborowski M. Applications of metabolomics in cancer studies. Adv Exp Med Biol. 2017;965.
Baker SG. Cancer screening markers: a simple strategy to substantially reduce the sample size for validation. Med Decis Mak. 2019;39.
Wright AA, et al. Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study Associations between palliative chemotherapy and adult cancer patients’ end of life care and place of death: prospective cohort study. BMJ. 2014; 348.
Wise PH. Cancer drugs survival and ethics. BMJ. 2016;355.
Ventola CL. Cancer immunotherapy Part 2: Efficacy safety and other clinical considerations. P T. 2017;42.
Temel JS, et al. Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non–small-cell lung cancer: Results of a randomized study of early palliative care. J. Clin. Oncol. 2011;29.
Rauniyar A, et al. Federated learning for medical applications: A taxonomy current trends. Challenges and Future Research Directions; 2022.
Witkiewicz AK, Wright TC, Ferenczy A, et al. Carcinoma and other tumors of the cervix. Blaustein’s Pathology of the Female Genital Tract. 2011;6:253–303.
Harada T, Sukoh N, Hakuma N. Pulmonary blastoma within bronchioloalveolar cell carcinoma. Respirology. 2006;11.
Isaacs R. Lymphosarcoma cell leukemia. Landmark Papers in Internal Medicine: the first 80 years of annals of internal medicine. 2009;441.
Fonseca R, Valdez R. Plasma cell neoplasms. Diagnostic Techniques in Hematological Malignancies. 2002;244:30–36.
Cupedo T, Coles MC, Veiga-Fernandes H. Development and structure of lymph nodes in humans and mice. Developmental Biology of Peripheral Lymphoid Organs. 2011;59–74.
Maresso KC, et al. Molecular cancer prevention: current status and future directions. CA: A Cancer Journal for Clinicians. 2015;65(5):345-383.
Anaya J, et al. A pan-cancer analysis of prognostic genes. PeerJ. 2016;3: e1499.
Lebeau A, et al, Invasive breast cancer: the current WHO classification. Der Pathologe 2014. 35:7-17.
Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Molecular Cancer 2007;6:1-13.
Goossens N, et al. Cancer biomarker discovery and validation. Translational cancer research 2015;4(3):256.
Brenner DR, et al. Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. Cancer Causes & Control. 2016;27:459-472.
Dobrolecki LE, et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer and Metastasis Reviews. 2016;35: 547-573.
Nardin S, et al. Breast cancer survivorship quality of life and late toxicities. Front Oncol. 2020; 10:864.
Bellanger M, et al. Are global breast cancer incidence and mortality patterns related to country-specific economic development and prevention strategies? J Glob Oncol. 2018;4:1-16.
Francies FZ, et al. Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options. Am J Cancer Res. 2020;10(5): 1568-1591.
Religioni U, Cancer incidence and mortality in Poland. Clinical Epidemiology and Global Health. 2020;8(2):329-334.
Lakhani SR, et al. WHO Classification of Tumours of the Breast; 2012.
Lima SM, Kehm RD, Terry MB. Global breast cancer incidence and mortality trends by region age-groups and fertility patterns. E Clinical Medicine. 2021;38: 100985.
Kudela E, et al. Breast cancer in young women: status quo and advanced disease management by a predictive preventive and personalized approach. Cancers. 2019;11(11):1791.
Torre LA, et al. Global cancer in women: burden and trendsglobal cancer in women: burden and trends. Cancer Epidemiology Biomarkers & Prevention. 2017;26(4):444-457.
Brinton LA, et al. Menstrual factors and risk of breast cancer. Cancer Invest. 1988; 6(3):245-54.
de Blok CJ, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. 2019;365.
Cancer CGoHFiB. Menarche menopause and breast cancer risk: individual participant meta-analysis including 118 964 women with breast cancer from 117 epidemiological studies. The Lancet Oncology. 2012;13(11):1141-1151.
Sisti JS, et al. Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies. Int J Cancer. 2016;138(10):2346-56.
Ferlay J, et al. Cancer incidence and mortality worldwide: sources methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015; 136(5):E359-E386.
TNM classification of malignant tumours. Hoboken NJ: Wiley; 2011.
Abramson VG, et al. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015;121.
Ades F, et al. Luminal B breast cancer: molecular characterization clinical management and future perspectives. J Clin Oncol. 2014;32.
Allison KH, et al. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology / College of American Pathologists guideline update. Arch Pathol Lab Med. 2020;144.
Amin MB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017. 67.
Anders CK, Carey LA. Biology metastatic patterns and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9.
Arpino G, et al, Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6.
Asselain B, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19.
Badve S, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24.
Bae SY, et al. Mucinous carcinoma of the breast in comparison with invasive ductal carcinoma: clinicopathologic characteristics and prognosis. J Breast Cancer. 2011;14.
Choi J, Jung WH, Koo JS. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. Histol Histopathol. 2012;27.
Curtis C, et al. The genomic and transcriptomic architecture of 2 000 breast tumours reveals novel subgroups. Nature. 2012;486.
Dowsett M, et al. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor–positive breast cancer treated with 5 years of endocrine therapy: CTS5. J Clin Oncol. 2018;36.
Sparano JA, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379.
Bianchini G, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674-690.
Bjarnadottir O, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013;138(2):499-508.
Blanco E, et al. Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther. 2014;22(7):1310-1319.
Bonnefoi H, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016;27(5):812-8.
Chan SM, et al. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood. 2007;110(1):278-86.
TNM classification of malignant tumours. John Wiley and Sons: Chichester; 2017.
Giuliano AE, et al. Breast cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67.
Ogawa Y, et al. Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer. 2004;11:267-275.
Hendry S, Salgado R.and T. Gevaert Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1: assessing the host immune response TILs in invasive breast carcinoma and ductal carcinoma in situ metastatic tumor deposits and areas for further research. Adv Anat Pathol 2017. 24.
Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Advances in Anatomic Pathology. 2005; 12(1):10-19.
Hortobagyi G, et al. Breast in AJCC cancer staging manual M.B. Amin S.B. Edge and F.L. Greene Editors. Springer: New York; 2017.
Shi F, et al. One-step nucleic acid amplification assay is an accurate technique for sentinel lymph node biopsy of breast cancer patients: a meta-analysis. Br J Cancer. 2017;117.
Davies C, et al. Early Breast Cancer Trialists′ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84.
Zombori T, et al. Evaluation of anatomic and prognostic stages of breast cancer according to the 8th edition of the TNM staging system—retrospective analysis based on data from deceased patients once diagnosed with breast cancer. Orv Hetil. 2017;158.
Wazir U, et al. Pleomorphic lobular carcinoma in situ: current evidence and a systemic review. Oncol Lett. 2016;12.
Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998; 339(22):1609-18.
Regan MM, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8• 1 years median follow-up. The Lancet Oncology. 2011; 12(12):1101-1108.
Makki J, Diversity of breast carcinoma: histological subtypes and clinical relevance. Clinical Medicine Insights: Pathology. 2015;8:CPath. S31563.
Rakha E, Ellis IO. An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens. Journal of Clinical Pathology. 2007;60(12):1300-1306.
Wysocka J, New WHO classification of breast tumours–as published in 2019. Nowotwory. Journal of Oncology. 2020;70(6):250-252.
Tan PH, et al. WHO classification of tumours editorial board. The 2019 world health organization classification of tumours of the breast. Histopathology. 2020;77(2):181-185.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up. Histopathology. 1991;19(5):403-410.
Amin MB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA: A Cancer Journal for Clinicians. 2017;67(2):93-99.
de Boer M, et al. Breast cancer prognosis and occult lymph node metastases isolated tumor cells and micrometastases. Journal of the National Cancer Institute. 2010;102(6):410- 425.
Tan LK, et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. Journal of Clinical Oncology. 2008;26(11):1803-1809.
Goldhirsch A, et al, Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annals of Oncology. 2009;20(8):1319-1329.
Howell A, et al. Results of the ATAC (Arimidex Tamoxifen Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453): 60-2.
Fisher B, et al, Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol. 1988;6(7):1076-87.
Hähnel R, Woodings T, Brian Vivian A. Prognostic value of estrogen receptors in primary breast cancer. Cancer. 1979;44(2):671-675.
Moja L, et al, Trastuzumab containing regimens for early breast cancer. Cochrane Database of Systematic Reviews. 2012(4).
Piccart-Gebhart MJ, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine. 2005;353(16):1659-1672.
Smith I, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet. 2007;369(9555):29-36.
Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine. 2005; 353(16):1673-1684.
Perez E, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Journal of Clinical Oncology. 2007;25(18_suppl):512-512.
Smith AE, et al. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat Commun. 2021; 12(1):6667.
de Azambuja E, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients. Br J Cancer. 2007; 96(10):1504-13.
Curigliano G, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of Oncology. 2017; 28(8):1700-1712.
Burstein H.J, et al, Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Annals of Oncology 2019;30(10):1541-1557.
Zhang Y, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021;39(12):1578-1593.e8.